Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Schnog

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
The Netherlands Journal of Medicine|March 11, 2015
An unusual craving!E G Gerrits, J B Schnog
BJC Reports|November 8, 2024
Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefitJ B Schnog, A J Duits, M J Samson
JCO Oncology Practice|February 14, 2024
Pharmaceutical Industry Payments to Medical Oncologists in the Netherlands: Trends and Patterns Provided by an Open-Access Transparency Data SetJ B Schnog, M J Samson, I Gersenbluth, et al.
Acta Haematologica|November 29, 2008
Increased serum levels of anti-angiogenic factors soluble fms-like tyrosine kinase and soluble endoglin in sickle cell diseaseP P Landburg, H Elsenga, J B Schnog, et al.
Journal of Cancer Policy|March 25, 2025
Characteristics of professional society oncological drug evaluation in the Netherlands from 2016 to 2020: A retrospective analysisB M F Penninx, M J Samson, A J Duits, et al.
Cancer Medicine|April 14, 2026
The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related IssuesS L Gerritse, E van Meerten, A J Duits, et al.
American Journal of Hematology|July 11, 2008
Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinibR M Van Hest, J B Schnog, M B Van't Veer, et al.
Clinical Immunology (Orlando, Fla.)|August 31, 2000
Duffy phenotype does not influence the clinical severity of sickle cell diseaseJ B Schnog, S O Keli, R A Pieters, et al.
European Journal of Haematology|December 17, 1998
Elevated IL-8 levels during sickle cell crisisA J Duits, J B Schnog, L R Lard, et al.
Journal of Pediatric Hematology/Oncology|March 7, 2002
Folate status assessment and folic acid supplements in sickle cell diseaseJ B Schnog, F P van der Dijs, M R Fokkema, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
The Netherlands Journal of Medicine|March 11, 2015
An unusual craving!E G Gerrits, J B Schnog
BJC Reports|November 8, 2024
Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefitJ B Schnog, A J Duits, M J Samson
JCO Oncology Practice|February 14, 2024
Pharmaceutical Industry Payments to Medical Oncologists in the Netherlands: Trends and Patterns Provided by an Open-Access Transparency Data SetJ B Schnog, M J Samson, I Gersenbluth, et al.
Acta Haematologica|November 29, 2008
Increased serum levels of anti-angiogenic factors soluble fms-like tyrosine kinase and soluble endoglin in sickle cell diseaseP P Landburg, H Elsenga, J B Schnog, et al.
Journal of Cancer Policy|March 25, 2025
Characteristics of professional society oncological drug evaluation in the Netherlands from 2016 to 2020: A retrospective analysisB M F Penninx, M J Samson, A J Duits, et al.
Cancer Medicine|April 14, 2026
The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related IssuesS L Gerritse, E van Meerten, A J Duits, et al.
American Journal of Hematology|July 11, 2008
Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinibR M Van Hest, J B Schnog, M B Van't Veer, et al.
Clinical Immunology (Orlando, Fla.)|August 31, 2000
Duffy phenotype does not influence the clinical severity of sickle cell diseaseJ B Schnog, S O Keli, R A Pieters, et al.
European Journal of Haematology|December 17, 1998
Elevated IL-8 levels during sickle cell crisisA J Duits, J B Schnog, L R Lard, et al.
Journal of Pediatric Hematology/Oncology|March 7, 2002
Folate status assessment and folic acid supplements in sickle cell diseaseJ B Schnog, F P van der Dijs, M R Fokkema, et al.
Pageof 3